Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Core Viewpoint - Cardiol Therapeutics Inc. has filed a preliminary prospectus supplement for a proposed public offering of Class A common shares to support the clinical development of its anti-inflammatory and anti-fibrotic therapies for heart disease [3][4]. Group 1: Offering Details - The offering is part of a registration statement declared effective by the SEC on July 16, 2024, under the Multijurisdictional Disclosure System between Canada and the United States [3]. - The net proceeds from the offering will be used for the clinical development of CardiolRx for recurrent pericarditis, as well as for general administrative expenses and working capital [4]. - Canaccord Genuity is acting as the sole bookrunner for the offering, which will be priced based on market conditions [4][5]. Group 2: Regulatory and Compliance - The closing of the offering is subject to customary conditions, including the listing of the common shares on the Toronto Stock Exchange and the Nasdaq, along with any required approvals [5]. - The preliminary prospectus supplement and accompanying base prospectus contain detailed information about the offering and can be accessed on SEDAR+ and EDGAR [6].